$1.5 Billion is the total value of Palo Alto Investors LP's 37 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALDR | ALDER BIOPHARMACEUTICALS INC | $35,110,000 | +60.2% | 1,861,630 | 0.0% | 2.34% | +119.6% | |
| ALGN | ALIGN TECHNOLOGY INC | $26,687,000 | -33.9% | 147,505 | 0.0% | 1.78% | -9.4% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $15,132,000 | -15.3% | 1,405,680 | 0.0% | 1.01% | +16.0% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $4,765,000 | -8.8% | 331,813 | 0.0% | 0.32% | +24.8% | |
| ALIM | ALIMERA SCIENCES INC | $1,707,000 | -36.4% | 3,013,793 | 0.0% | 0.11% | -12.3% | |
| CYTK | CYTOKINETICS INC | $1,408,000 | +1.2% | 123,686 | 0.0% | 0.09% | +38.2% | |
| ZGNX | ZOGENIX INC | $1,181,000 | -16.2% | 29,500 | 0.0% | 0.08% | +14.5% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $837,000 | -0.9% | 1,162,473 | 0.0% | 0.06% | +36.6% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $387,000 | -12.2% | 73,500 | 0.0% | 0.03% | +23.8% | |
| NERV | MINERVA NEUROSCIENCES INC | $281,000 | +37.7% | 36,319 | 0.0% | 0.02% | +90.0% | |
| IDRA | IDERA PHARMACEUTICALS INC | $223,000 | +8.3% | 77,044 | 0.0% | 0.02% | +50.0% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $193,000 | -62.9% | 125,321 | 0.0% | 0.01% | -48.0% | |
| SPHS | SOPHIRIS BIO INC | $144,000 | -31.1% | 247,000 | 0.0% | 0.01% | 0.0% | |
| MLNTQ | MELINTA THERAPEUTICS INC | $39,000 | -41.8% | 10,137 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Biomarin Pharmaceuticals, Inc | 42 | Q3 2023 | 16.6% |
| UNITED THERAPEUTICS CORP DEL | 42 | Q3 2023 | 15.3% |
| INSMED INC | 42 | Q3 2023 | 14.1% |
| STAAR Surgical Company | 42 | Q3 2023 | 11.8% |
| AMICUS THERAPEUTICS INC | 42 | Q3 2023 | 12.1% |
| VANDA PHARMACEUTICALS INC | 42 | Q3 2023 | 5.8% |
| PROTHENA CORP PLC | 42 | Q3 2023 | 9.1% |
| CYTOKINETICS INC | 40 | Q3 2023 | 0.4% |
| ALIGN TECHNOLOGY INC | 39 | Q3 2023 | 2.5% |
| ABIOMED INC | 38 | Q3 2022 | 17.1% |
View Palo Alto Investors LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ALIMERA SCIENCES INCSold out | April 03, 2023 | 0 | 0.0% |
| Epizyme, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| INSMED Inc | February 14, 2023 | 5,871,291 | 4.3% |
| Vanda Pharmaceuticals Inc. | February 14, 2023 | 1,087,064 | 1.4% |
| ALIMERA SCIENCES INC | February 14, 2022 | 802,423 | 11.6% |
| Clovis Oncology, Inc. | February 14, 2022 | 3,997,826 | 3.1% |
| STAAR SURGICAL CO | February 14, 2022 | 1,140,511 | 2.4% |
| Aimmune Therapeutics, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| AMAG PHARMACEUTICALS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
| ALIMERA SCIENCES INC | February 14, 2020 | 802,424 | 16.2% |
View Palo Alto Investors LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-04-03 |
| 4 | 2023-03-28 |
View Palo Alto Investors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.